ONCO Onconetix, Inc. NASDAQ · United States

Onconetix (ONCO) news ONCO reverse split, delisting and offering news

Listings · Oct 26, 2026

Onconetix sets a 1-for-10 reverse stock split for November 6

The split cuts the share count to about 588,677 from roughly 5,886,774. The stock keeps trading on Nasdaq as ONCO under a new CUSIP.

Latest Onconetix news

Sep 14, 2026Company Updates
Onconetix provides $2.5 million bridge advance to Realbotix before acquisition
The bridge facility provides up to $5,000,000 to Realbotix LLC, the target of a pending all-stock share exchange, with an initial advance of $2,500,000.
Jul 28, 2026Financings
Onconetix sells $30,249,600 of Series F preferred in PIPE financing
The securities purchase agreement covers 37,812 shares of Series F convertible preferred stock with an initial conversion price of $0.9767 per share.
May 19, 2026Listings
Onconetix to effect 1-for-10 reverse stock split on May 21, 2026
The Board fixed the ratio under a stockholder authority approved April 30, 2026, to help keep the stock above Nasdaq's $1.00 minimum bid price.
May 13, 2026Company Updates
Onconetix reports Q1 2026 progress at Proteomedix
The Swiss unit added two peer-reviewed papers, began enrolling in a U.S. validation study with Labcorp and kept expanding sales in Europe. The release does not report quarterly revenue or cash.
Apr 24, 2026Company Updates
Onconetix directors Oakley and Meier resign; Dorf named chairman
Josh Epstein joined the board on April 23, 2026 and chairs its Nominating and Corporate Governance Committee. The 8-K says neither resignation involved a disagreement with management.
Oct 3, 2025Financings
Onconetix sells convertible preferred and warrants for approximately $6.25 million
Institutional investors bought 7,813 shares of Series E convertible preferred stock and warrants for 2,025,223 common shares. The preferred converts at $3.8576.
Jul 16, 2025Mergers
Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%
Onconetix holders would keep 10% of the combined company. Closing was expected in the fourth quarter of 2025, subject to regulatory, stockholder and third-party approvals.
May 22, 2025Listings
Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone
Nasdaq flagged the missing quarterly report on May 20, 2025 as another basis for delisting, ahead of a Panel hearing set for May 27, 2025. Onconetix also issued a promissory note to Keystone Capital Partners for a $250,000.00 purchase price.
Apr 1, 2025Distress
Onconetix files NT 10-K late filing notice, says cash fell to $0.6 million at year end
Onconetix needs more time to finalize its 2024 financial statements and expects to file within the fifteen-day grace period. It flagged lower cash, goodwill and intangibles, and new subscription and warrant liabilities.
Apr 1, 2025Distress
Onconetix delays 10-K as cash falls to $0.6 million at year end
The company expects to file within the 15-day grace period. Its cash was about $4.6 million at the end of 2023.

What Onconetix does

Onconetix, Inc. describes itself as a commercial stage biotechnology company focused on men's health and oncology. Its main product is Proclarix, a protein-based blood test for prostate cancer that uses the same sample as a regular PSA test. Proclarix helps doctors and patients with unclear PSA results decide whether a biopsy is needed. It is approved for sale in the European Union under the In Vitro Diagnostic Regulation, and the company expects to market it in the United States as a lab developed test through its license agreement with LabCorp. Onconetix acquired ENTADFI, an FDA-approved once-daily pill for BPH, in April 2023, but abandoned its commercialization and no longer holds inventory of the product. The company relies on third-party manufacturers, with single-source suppliers for commercial product. As of December 31, 2025, it reported cash of approximately $5.2 million, and the filing states that substantial doubt exists about its ability to continue as a going concern. In February 2026 it entered into a share exchange agreement with Realbotix Corp.

Product or program	What it is	Stage
Proclarix	Blood test to help diagnose prostate cancer in patients with unclear PSA results	Approved for sale in the European Union
ENTADFI	Once-daily finasteride and tadalafil pill for BPH	FDA-approved; commercialization abandoned

Summarised from the company's 10-K filed Mar 13, 2026.

Onconetix annual financials

Line	FY2025	FY2024
Revenue	$815,371	$2.5 million
Research and development		$154,359
Net income (loss)	-$14.0 million	-$58.7 million
Cash from operations	-$9.7 million	-$10.5 million
Cash and equivalents	$5.2 million	$646,500

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.9 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Onconetix

Did Onconetix do a reverse stock split?

Our latest story on this, dated Oct 26, 2026: "Onconetix sets a 1-for-10 reverse stock split for November 6". The story links the filing or release it is based on. Read the story.

Was Onconetix delisted?

Our latest story on this, dated May 22, 2025: "Onconetix gets Nasdaq notice for unfiled 10-Q, issues $294,117.65 note to Keystone". The story links the filing or release it is based on. Read the story.

Has Onconetix raised money recently?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. Read the story.

Has Onconetix sold convertible notes?

Our latest story on this, dated Jul 28, 2026: "Onconetix sells $30,249,600 of Series F preferred in PIPE financing". The story links the filing or release it is based on. Read the story.

Has Onconetix received a Nasdaq deficiency notice?

Is Onconetix involved in a merger or acquisition?

Our latest story on this, dated Jul 16, 2025: "Onconetix signs merger deal with Ocuvex; Ocuvex holders would own 90%". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Onconetix?

Onconetix, Inc. trades under the ticker ONCO on NASDAQ.

Where is Onconetix listed?

Onconetix, Inc. is listed on NASDAQ.

What is the SEC CIK of Onconetix?

The SEC Central Index Key (CIK) for Onconetix, Inc. is 1782107. Its filings are on SEC EDGAR.

How many shares does Onconetix have outstanding?

3,949,107 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Onconetix listed under?

Our directory records Onconetix, Inc. under United States.

What does Onconetix do?

Our directory classifies Onconetix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Onconetix?

The ISIN recorded for Onconetix, Inc. is US68237Q4010.

Does aibio.space cover Onconetix?

aibio.space lists Onconetix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is Onconetix incorporated?

SEC records list its state or country of incorporation as DE.

Investor discussion: Onconetix

Members talk about Onconetix (ONCO). Reader posts, not aibio.space reporting, and not investment advice.

Rules

Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Onconetix, newest first. Each line links the filing it comes from.

Oct 26, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). Source
Oct 23, 2026Mergers
Filed documents for a merger or acquisition. SEC Form 425. Source
Oct 7, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Sep 17, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Jul 29, 2026Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Jun 24, 2026Mergers
Filed documents for a merger or acquisition. SEC Form 425. Source
May 19, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
May 4, 2026Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Mar 30, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Mar 27, 2026Listings
Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). Source
Mar 18, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Mar 13, 2026Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. Source
Feb 12, 2026Mergers
Filed documents for a merger or acquisition. SEC Form 425. Source
Feb 9, 2026Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
Jan 2, 2026Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Dec 22, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Nov 10, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Oct 29, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Oct 3, 2025Financings
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Sep 22, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Jul 16, 2025Mergers
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.02,8.01,9.01). Source
Jun 16, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,9.01). Source
Jun 11, 2025Listings
Reported a reverse stock split. SEC Form 8-K (Items 1.01,2.03,3.03,5.03,7.01,9.01). Source
Jun 5, 2025Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). Source
May 22, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 1.01,2.03,3.01,9.01). Source
Apr 30, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Apr 30, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). Source
Apr 18, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01). Source
Apr 18, 2025Listings
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Apr 8, 2025Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:ONCO on TradingView.

SEC filings and registration

SEC name: Onconetix, Inc.
CIK: 1782107
Industry (SIC): Pharmaceutical Preparations (2834)
US tickers: ONCO (Nasdaq)
State or country of incorporation: DE
Fiscal year ends: December 31
Filer category: <br>Emerging growth company
Business address: 201 E. FIFTH STREET, CINCINNATI, OH, 45202
Phone: 513-620-4101
Shares outstanding: 3,949,107 as of 2026-08-13 (10-Q filed 2026-08-13)
Former names: Blue Water Biotech, Inc.; Blue Water Vaccines Inc.

Recent filings (8-K and 6-K are the company's own announcements)

DEF 14A filed 2026-10-07
8-K filed 2026-09-14
10-Q filed 2026-08-13
S-1 filed 2026-08-12
8-K filed 2026-07-29
S-1 filed 2026-06-09
8-K filed 2026-05-19
8-K filed 2026-05-14

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Onconetix, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker ONCO, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company: Onconetix, Inc.
Ticker: ONCO
Listing: NASDAQ
Country or territory: United States
Business scope: Pharmaceuticals: Major
ISIN: US68237Q4010
Last quote in directory: 2026-10-21
Directory source: Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction